Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1998

View Archived Issues

Company Profile: GenVec

Prodrug of platelet gpIIb/IIIa receptor antagonist with excellent intranasal antithrombotic efficacy

Cerus presents preclinical data on RBC pathogen inactivation system and begins clinical trials

European merger mania continues with the proposed formation of AstraZeneca

CoCensys patents key cell death gene, will license the technology out

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Magainin scientists identify new therapeutic target for asthma: interleukin-9

Banyu conducts PK and metabolic studies of topoisomerase I inhibitor

Merck & Co. revises safety information on Singulair for U.S. healthcare professionals

Excellent results obtained in AML patients receiving Maxamine plus IL-2

CIMA reports significant transmucosal absorption-enhancing effects for OraVescent

First report of efficacy of oral, sustained-release fampridine in SCI

Pharmacyclics' photoangioplasty a hot topic at RSNA

LY-303366: therapeutic and prophylactic efficacy in pulmonary aspergillosis in neutropenic animals

FDA advisory committee will meet in January to review KeraVision Ring PMA

Hemosol completes patient recruitment in phase II trial with Hemolink

New approval obtained for Nycomed's Xefo

CMA-676 shows efficacy and excellent tolerability in patients with AML

Aronex files first NDA for orphan drug for APL

J&J to terminate collaboration with Ergo Science for Ergoset development

Lilly obtains exclusive worldwide rights to (R)-fluoxetine

Techniclone initiates phase II trial for treatment of malignant glioma

Competitive LPS antagonist E-5531 suppresses LPS-mediated effects in vitro and in vivo

Candidate antidepressants available for licensing from Berkeley Lab

Avant receives further payment from Novartis for TP-10 development

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026